Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH ALHALEL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1700830353
CMS profile
32241
Location
MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$447.58

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $447.58 24

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH ALHALEL

NPI 1700830353 · CMS profile ID 32241

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700830353?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700830353?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700830353?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1700830353?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $447.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $20.3011/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394064 CMS
ABBVIE INC. $13.3310/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394062 CMS
Madrigal Pharmaceuticals $27.6110/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248230203 CMS
ABBVIE INC. $21.7510/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394060 CMS
Aimmune Therapeutics, Inc. $23.0609/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249671126 CMS
Phathom Pharmaceuticals, Inc. $22.4008/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219244148 CMS
ABBVIE INC. $12.6207/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394058 CMS
Gilead Sciences, Inc. $16.7607/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234559677 CMS
ABBVIE INC. $12.7707/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394056 CMS
ABBVIE INC. $23.0407/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394054 CMS
ABBVIE INC. $7.8106/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394052 CMS
ABBVIE INC. $20.4606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394050 CMS
ABBVIE INC. $10.1205/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394048 CMS
ABBVIE INC. $5.1104/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394046 CMS
Janssen Biotech, Inc. $31.6704/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175099464 CMS
ABBVIE INC. $21.5504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394042 CMS
ABBVIE INC. $2.5704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394044 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.6803/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231985404 CMS
Gilead Sciences, Inc. $21.5002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234510381 CMS
ABBVIE INC. $27.3401/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394040 CMS
ABBVIE INC. $15.1101/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394038 CMS
ABBVIE INC. $25.6001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201394036 CMS
PFIZER INC. $21.8901/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229643047 CMS
EVOKE PHARMA, INC. $24.5301/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243911935 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $749.94 37
PY2020 $420.45 27
PY2021 $703.45 46
PY2022 $1,041.54 42
PY2023 $775.96 21
PY2024 $1,310.53 38
PY2025 $447.58 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $352,790.88 227
PY2024 Principal investigator $269,533.46 68
PY2023 Principal investigator $335,027.89 61
PY2022 Recipient $1.00 1
PY2022 Principal investigator $35,164.94 37
PY2021 Recipient $938.46 1
PY2021 Principal investigator $34,998.93 15
PY2020 Principal investigator $98,605.96 19
PY2019 Recipient $9,135.15 2
PY2019 Principal investigator $18,309.40 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $5,616.00 12/29/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254847
Principal investigator 1 Genentech, Inc. $4,212.00 12/22/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254799
Principal investigator 1 Genentech, Inc. $11,232.00 12/20/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254861
Principal investigator 1 Genentech, Inc. $1,404.00 12/08/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254813
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $108.00 12/08/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039771787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,427.00 12/01/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039768829
Principal investigator 1 Genentech, Inc. $2,808.00 11/16/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254711
Principal investigator 1 Genentech, Inc. $4,212.00 11/09/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 11/03/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039770149
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,927.00 11/03/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039770161
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,362.00 11/03/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039770167
Principal investigator 1 Eli Lilly and Company $25,275.00 10/04/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1038071617
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 09/15/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039761735
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 09/15/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039805315
Principal investigator 1 Genentech, Inc. $4,212.00 09/12/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253919
Principal investigator 1 Eli Lilly and Company $859.89 09/11/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1038073325
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,934.00 09/01/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039761135
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,934.00 09/01/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039804513
Principal investigator 1 Genentech, Inc. $2,808.00 08/31/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254005
Principal investigator 1 Genentech, Inc. $2,808.00 08/21/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254271
Principal investigator 1 Genentech, Inc. $16,848.00 08/14/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254141
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $74.00 08/14/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039760533
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $363.00 08/14/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039760539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $74.00 08/14/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039803703
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $363.00 08/14/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039803711
Principal investigator 1 Genentech, Inc. $21,060.00 08/08/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254107
Principal investigator 1 Genentech, Inc. $4,212.00 07/27/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253935
Principal investigator 1 Genentech, Inc. $19,656.00 07/24/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254173
Principal investigator 1 Genentech, Inc. $11,232.00 07/11/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040254057
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 06/30/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046556391
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 06/30/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046556593
Principal investigator 1 Genentech, Inc. $400.00 06/19/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253871
Principal investigator 1 Genentech, Inc. $11,232.00 06/05/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253531
Principal investigator 1 Genentech, Inc. $400.00 06/01/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253805
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 05/31/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046556744
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 05/31/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046557407
Principal investigator 1 Genentech, Inc. $87,048.00 05/25/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253565
Principal investigator 1 Genentech, Inc. $400.00 05/11/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253661
Principal investigator 1 Genentech, Inc. $400.00 05/11/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253855
Principal investigator 1 Genentech, Inc. $400.00 05/01/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253631
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 04/28/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046556371
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 04/28/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046556409
Principal investigator 1 Genentech, Inc. $800.00 04/27/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253903
Principal investigator 1 Genentech, Inc. $1,600.00 04/24/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253677
Principal investigator 1 Genentech, Inc. $2,000.00 04/24/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253759
Principal investigator 1 Genentech, Inc. $5,600.00 04/20/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253709
Principal investigator 1 Genentech, Inc. $4,000.00 04/20/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253821
Principal investigator 1 Genentech, Inc. $28,500.00 04/11/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253598
Principal investigator 1 Genentech, Inc. $10,000.00 04/10/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040253789
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 03/31/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046558179
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 03/31/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046558399
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 02/28/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046558415
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 02/28/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046558449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 02/01/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet No dispute reported 06/30/2026 1039843979
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 01/31/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046557385
Principal investigator 1 ARENA PHARMACEUTICALS, INC. $28.00 01/31/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046558431
Principal investigator 1 Eli Lilly and Company $500.00 01/09/2023 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 1038070441
Principal investigator 1 PFIZER INC. $50.00 01/09/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046485115
Principal investigator 1 PFIZER INC. $700.00 01/09/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046488527
Principal investigator 1 PFIZER INC. $75.00 01/09/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046506481
Principal investigator 1 PFIZER INC. $6.00 01/09/2023 Non-covered Recipient Entity
Rio Grande Gastroenterology
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1046507795